Bulletin from the Extraordinary General Meeting on March 27, 2017

On the 27th of March, 2017, Vicore Pharma Holding AB (publ) held an Extraordinary General Meeting. The following resolutions, among others, were passed.

Amendment of the Articles of Association
To enable the board of directors' resolution to issue new shares, resolved 23rd February 2017, the general meeting resolved to change the limits for the total number of shares and the share capital in the Articles of Association. The share capital shall be not less than SEK 2,500,000 and not more than SEK 10,000,000. The number of shares shall be not less than 5,000,000 and not more than 20,000,000.

Approval of the Board's resolution to issue new shares
It was resolved to approve the board of directors’ resolution to issue new shares, resolved on 23rd February 2017, through which the share capital will increase with SEK 750,000 through a directed share issue of 1,500,000 new shares. Right to subscribe for new shares shall, with deviation from the shareholders’ pre-emption rights, only fall upon certain selected strategic and institutional investors. The reasons for the deviation from the shareholders’ pre-emption rights are that the company shall, in a timely manner, ensure to secure the company’s capital need for the operations, as well as to broaden the ownership structure of the company with strategic and institutional investors

The subscription price for the share issue was on 23 February 2017 determined to SEK 16 per share. The subscription price has been determined through a so called private placement procedure. 

 
For further information, please contact:

Göran Wessman, Chairman
Tel: 0708-16 14:50 or e-mail: goran.wessman@vicorepharma.com

Nina Carlen, IR, Communications & Administration Coordinator
Tel: 0763-90 94 04 or e-mail: nina.carlen@vicorepharma.com

 
About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2 agonists as a new and effective class of small molecule drugs. Our lead candidate, C21 is being developed for the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com 

 
This information is such information that Vicore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5:00 pm CEST on March 27, 2017.

 

Vicore Pharmas share is listed on NASDAQ Stockholm, First North under the ticker VICO.
The company´s Certified Adviser is Redeye AB.

Vicore Pharma Holding AB (publ) | c/o Bioventurehub, Pepparedsleden 1, SE-431 83 Mölndal
Phone: +46 (0)31 78 80 560 | Org nr 556680-3804 | www.vicorepharma.com

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links